Journal profile · ENDOCRINOLOGY & METABOLISMIMMUNOLOGY-IMMUNOLOGY
Endocrine Metabolic & Immune Disorders-Drug Targets
ISSN 1871-5303 · eISSN 2212-3873 · Bentham Science Publishers B.V. · U ARAB EMIRATES
Endocrine Metabolic & Immune Disorders-Drug Targets: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 1.95; hybrid open access; median 92 days to acceptance (65 articles, last 24 months); 191 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Endocrine Metabolic & Immune Disorders-Drug Targets is published by Bentham Science Publishers B.V. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Thyroid Disorders and Treatments, Adipokines, Inflammation, and Metabolic Diseases and Diabetes and associated disorders, together about 22.4% of its articles. Its main subfields are Endocrinology, Diabetes and Metabolism. (generated from OpenAlex topic counts and CAS ranking data)
Aims & Scope This journal is devoted to timely reviews and original articles of experimental and clinical studies in the field of endocrine, metabolic, and immune disorders. Specific emphasis is placed on humoral and cellular targets for natural, synthetic, and genetically engineered drugs that enhance or impair endocrine, metabolic, and immune parameters and functions. Moreover, the topics related to effects of food components and/or nutraceuticals on the endocrine-metabolic-immune axis and on microbioma composition are welcome.
Source: LetPub
Research area (LetPub): ENDOCRINOLOGY & METABOLISMIMMUNOLOGY-IMMUNOLOGY
Main research topics OpenAlex counts of recent articles; shares are approximate
- Thyroid Disorders and TreatmentsMedicine9.2%
- Adipokines, Inflammation, and Metabolic DiseasesMedicine7.1%
- Diabetes and associated disordersBiochemistry, Genetics and Molecular Biology6.1%
- Thyroid Cancer Diagnosis and TreatmentMedicine5.8%
- Natural Antidiabetic Agents StudiesMedicine4.9%
- Diabetes Treatment and ManagementMedicine4.4%
- Vitamin D Research StudiesMedicine4.3%
- Diabetes, Cardiovascular Risks, and LipoproteinsMedicine4.3%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Endocrinology & Metabolism | Zone 4 |
| Minor | Immunology | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Endocrinology & Metabolism | Zone 4 |
| Minor | Immunology | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Endocrinology & Metabolism | Zone 4 |
| Minor | Immunology | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 1.95LetPub ·
- CiteScore 2026-06
- 4.1LetPub ·
- SJR 2026-06
- 0.55LetPub ·
- SNIP 2026-06
- 0.56LetPub ·
- h-index
- 44LetPub ·
- h-index
- 67OpenAlex ·
- i10-index
- 735OpenAlex ·
- 2-year mean citedness
- 1.46OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 17.09%LetPub ·
Volume
- Articles per year
- 69LetPub ·
Articles by year OpenAlex count · 2,155 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 166 | 70 | 6 |
| 2025 | 191 | 131 | 221 |
| 2024 | 166 | 38 | 534 |
| 2023 | 211 | 22 | 1,092 |
| 2022 | 173 | 20 | 1,358 |
| 2021 | 162 | 16 | 1,466 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
92 daysMedian, submission to acceptance · P25–P75 68 days – 118 days
- Acceptance to online
- median 131 days (65 articles)
- Submission to online
- median 216 days
- Sample
- 65 articles with submission and acceptance dates (498 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Bentham Science Publishers B.V.
- Country or region
- U ARAB EMIRATES
- Language
- English
- ISSN
- 1871-5303
- Electronic ISSN
- 2212-3873
- Official links
- Journal homepage ↗LetPub
- Submission system ↗LetPub
FAQ
Frequently asked questions about Endocrine Metabolic & Immune Disorders-Drug Targets
What CAS zone is Endocrine Metabolic & Immune Disorders-Drug Targets in?
In the 2025 upgraded edition of the CAS Journal Ranking, Endocrine Metabolic & Immune Disorders-Drug Targets is in Zone 4 of Medicine, and in Zone 4 of the minor category Endocrinology & Metabolism / Immunology / Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Endocrine Metabolic & Immune Disorders-Drug Targets?
The latest impact factor listed by LetPub is 1.95; CiteScore 4.1, h-index 67.
How long does peer review take at Endocrine Metabolic & Immune Disorders-Drug Targets?
Based on the dates recorded on 65 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 92 days (interquartile range 68–118 days). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Endocrine Metabolic & Immune Disorders-Drug Targets?
According to LetPub and DOAJ records, Endocrine Metabolic & Immune Disorders-Drug Targets is indexed in SCIE and Scopus.
Is Endocrine Metabolic & Immune Disorders-Drug Targets open access, and what is the APC?
Endocrine Metabolic & Immune Disorders-Drug Targets is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .